A group of pathologists who support drug discovery and who come from several pharmaceutical and biotechnology companies met informally this past November at the Annual Meeting of the American College of Veterinary Pathologists (in St. Louis, MO) to discuss the contribution of molecular pathology to the identification and subsequent characterization of potential therapeutic molecules during discovery. During this discussion, it became apparent that discovery pathologists are engaged in a variety of activities but that the specific activities differed among them, which in part reflects differences in their corporate organizations and cultures. It was decided that a series of invited commentaries describing the activities of discovery pathologists at specific pharmaceutical and biotechnology companies might be useful in order to highlight the institutional benefits of this approach and to identify additional ways to integrate pathology into discovery research programs. Since the organization and mission of pathology at Genentech may differ from that of more traditional pathology departments in the industry, I was asked to describe my experiences as a pathologist at Genentech. I came to Genentech as a pathologist 6 yr ago, after completing a Ph.D. and postdoctoral training, so my experience in drug discovery and development has been restricted to Genentech. During those 6 yr, Pathology has reported (at different times) through both the Development and Research organizations, which reflects the important contributions we make to both of these functional areas. Because Pathology supports both research and development activities at Genentech, we routinely bridge these 2 functional areas and are uniquely positioned to observe, integrate, and communicate data generated in one functional area to the other. Because the majority of our studies originate in Research, we have been physically and functionally located in Research for the past 3 yr. During this period, I have had the opportunity to support 3 molecules from the early research stage through development to the Investigational New Drug (IND) filing. I have seen firsthand the value of integrating pathologists into discovery programs as new molecules are identified and how information gained during these early studies can be incorporated into the design of the preclinical program. For example, histopathologic evaluation of the early proof of concept and efficacy studies for a novel hematopoietic factor in Research provided valuable information on expected morphologic changes and potential target tissues for the later Good Laboratory Practice (GLP) multidose toxicity studies. As a result, there were no unanticipated pathologic findings in the GLP studies; all findings had been previously described in the earlier in-house studies. At Genentech, the early identification (that is, in Research) of microscopic changes associated with administration of a molecule does not automatically &dquo;kill&dquo; the molecule but rather enables the preclinical safety program to anticipate these changes and to incorporate specific procedures to more directly characterize them.
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Pathologists at Genentech provide input into all stages of drug development; they are directly involved in new molecule-discovery programs and late-stage research and they support preclinical and clinical development programs for therapeutic candidates through to Biologic License Application filing. Since the integration of pathologists into these activities is facilitated by our corporate organization and culture, I would like to briefly describe the Research-Development model at Genentech and then enumerate some of the activities of the pathologists in the Research program. Currently, we have 6 pathologists at Genentech; 2 additional pathologists will be hired this year to provide in-depth support for investigative toxicology and mechanism-of-action studies for molecules in Development.
Potential therapeutic molecules are identified and extensively scrutinized while they are still in Research, prior to elevation to Development status. Generally, only a few molecules are selected for Development each year, so each is thoroughly scrutinized before reaching Development. Research studies, including proof of concept and relevant histopathology data (such as light microscopy, in situ hybridization, and immunohistochemistry) are reviewed by department directors in both Research and Development. After identification of a promising late-stage Research candidate, an initial project team, including a pathologist and a toxicologist, is formed to continue molecule selection and optimization of dose and route in the efficacy studies. Once a molecule has been selected for Development, specific project subteams are formed. One of these, the Pharmacology subteam, includes representatives from toxicology, pathology, pharmacokinetics/metabolism, clinical, assay services, and manufacturing in order to implement a preclinical safety program that supports the proposed clinical plan.
The initial preclinical toxicology program may include single and multidose toxicity, local tolerance, and he-molytic potential studies as well as tissue cross-reactivity studies for monoclonal antibody therapeutics. Since no GLP toxicology studies are conducted on the premises and because we do not have facilities for either dogs or primates, these studies are performed at contract laboratories, with the project toxicologist as the principle investigator. During the preclinical safety program, the pathologist interacts closely with the toxicologist, providing input into the study design and endpoints. The pathologist is involved in both protocol and report reviews for the GLP toxicology studies and usually examines a subset of the slides after the draft pathology report is issued in order to ensure that all lesions are completely and accurately recorded. The pathologist is also involved in any non-GLP investigative toxicology and pharmacokinetic/ tissue distribution studies that are initiated in-house. In addition to participation on the project subteams, the pathologist supports any additional Research studies with the molecule, acting as a liaison between Research and the project team in order to ensure that there is minimal duplication of efforts and resources.
The 6 pathologists in the Pathology Department are all board-certified (in anatomic pathology, anatomic and clinical pathology, or anatomic pathology and surgery), and they all have postdoctoral research experience. We are equally divided between veterinary and human medicine. This provides complementary training and expertise in a broad range of disease conditions. In enables us to identify potential therapeutic targets and animal models for Research and offers pathology expertise for both the preclinical and clinical programs in Development. For the past year, individual pathologists have been aligned with specific Research departments or focus areas, such as &dquo;Cardiovascular,&dquo; &dquo;Immunology,&dquo; &dquo;Molecular Oncology,&dquo; and &dquo;Neuro-endocrinology.&dquo; Pathologists are integrated into these focus areas by participation in their senior staff meetings, through review of all animal-use protocols, and via supervision of core labs supporting in vivo studies, and they also provide all necessary pathology support for studies originating in their focus area. This integration insures that all animal studies are consistent with departmental and corporate priorities and that they are well designed with appropriate endpoints in order to provide meaningful pathology data. By-off by the pathologist commits Pathology Department resources to support the studies; consequently, histology accessions of unexpected or poorly designed studies and poorly fixed or inappropriate tissues have been markedly reduced. By eliminating these unwanted submissions, Pathology Department resources are available to support other efforts, including those studies initiated by pathologists. In addition to laboratory space and dedicated technical support, each pathologist has access to the in situ hybridization and immunohistochemistry core labs in the department.
In Research, I support the transgenic and knock-out mouse programs and serve on the Animal Resource Committee, reviewing requests for resources (including space, technical, and pathology support) to generate, breed, and characterize gene-targeted mice. I also support activities related to 2 Development molecules, an angiogenic factor and a recombinant humanized monoclonal antibody against that angiogenic factor, as well as any Research studies with related molecules. I have 1 technician, and my lab primarily utilizes tissue-based techniques (immunohistochemistry, in situ hybridization, whole-mount immunohistochemistry, polymerase chain reaction, and laser capture microscopy) to characterize phenotypic changes in targeted mice, to evaluate efficacy models, to characterize gene and protein expression patterns, and to study the distribution of therapeutic molecules in specific models.
Overall, activities and opportunities for Research pathologists at Genentech include (a) involvement in different gene-discovery technologies and characterization of the output; (b) identification and characterization of novel gene-expression patterns or target therapeutic antigens in normal and diseased human and animal tissues (1-4, 14-16, 25, 27) ; (c) design and interpretation of in vivo assays to elucidate the activity or biological function of novel genes (6, 8, 9, 12) ; (d) identification and evaluation of potential therapeutic targets as well as new indications for existing therapeutics (5, 10, 11, 20) ; (e) development and characterization of animal models that replicate human disease in order to better understand the pathogenesis of disease or to evaluate potential therapeutics (22-24, 26, 28 ); (f) involvement with proof of concept studies and preliminary safety evaluation of specific therapeutics (7, 13, 21) ; and (g) participation in the development and evaluation of new technologies, delivery strategies, routes of administration, and formulations (17) (18) (19) . All of these activities depend on the unique skill set of pathologists, which includes the ability to recognize cellular and tissue-based changes in morphology, gene, and protein expression and to interpret the significance of these changes, based upon an understanding of normal development, physiology, and pathology. These activities overlap, complement, and extend the findings of our molecular and cell biology colleagues and place these findings in the context of the whole organism. They rely on the traditional tools of morphologic pathology (light, electron, and confocal microscopy) and standard specialized techniques (such as in situ hybridization, immunohistochemistry, microautoradiography, and morphometry) but also include newer technologies, such as DNA chips and arrays, laser capture microdissection, quantitative polymerase chain reaction, and embryology.
By integrating pathology into the early drug-discovery process, companies can capitalize on our familiarity with a wide variety of disease processes, which can be leveraged to identify potential therapeutic targets or pathways. As pathologists, we are able to procure and evaluate normal and diseased tissues for novel gene-discovery efforts and also to interpret the distribution and significance of the expression patterns of those novel genes. Our training enables us to identify and characterize (from the organismal to molecular level) animal models of human disease and to evaluate the effects of novel therapeutics in these models as well as any changes that may represent potential safety signals. For me, the advantages of being a pathologist in the discovery environment have included the continual exposure to new ideas and technologies, the rapid pace at which discoveries proceed, and the opportunities to collaborate and to intellectually contribute to a wide variety of projects and to see novel therapeutic molecules progress from initial cloning into the clinic.
However, there is still progress to be made if the contributions of pathology are to be realized to the fullest. Barriers to seamless integration of pathology in discovery research can involve concrete differences in focus, training, and salary but may also reflect the antiquated view of pathology as primarily a service department rather than a collaborative interaction. Although the &dquo;service mentality&dquo; may not be an institutionally held view, there are still individuals who resist the intellectual contribution a pathologist can make to their research program.
Some of this will evolve over time as pathologists are assimilated into research departments and focus areas and make a mark on the studies they support. The other way to demonstrate the impact pathologists can have in a research environment is to provide an opportunity (time, space, and resources) for pathologists to initiate their own investigative programs.
